

The T@blet

News from the Medicines Management Team

Issue 9 November 2019

CONTENTS

Priority information	1
Plavix (clopidogrel) revised SPC	1
Glibenclamide discontinued	2
Shortages	2
SSRI's SPC update	2
Safety Alerts Direct to Practices via Central Alerting System (CAS)	2
Self Care	3/4
Information	
Unlicensed Specials Flowchart	5
Opioid Reduction – Consultant Connect	5
APC prescribing Committee October UPDATE	5
Doncaster and Bassetlaw Formulary Liaison Group update	6
Cannabis-based products for medicinal use Training Package	6
Antimicrobial Guidance for Doncaster and Bassetlaw	6/7

PRIORITY INFORMATION

PLAVIX (CLOPIDOGREL) REVISED SPC

SPC now details that co-administration of opioids has the potential to delay and reduce the absorption of clopidogrel due to delayed gastric emptying. The use of parenteral antiplatelet agent in ACS should be considered where opioid co-administration is required.

Link here; [Revised SPC: Plavix \(clopidogrel\) tablets](#)

For general enquiries please email: donccg.medicinesmanagementadmin@nhs.net

For practice pharmacist queries please email: donccg.rxline@nhs.net

GLIBENCLAMIDE DISCONTINUED

Wockhardt have discontinued glibenclamide tablets and there are no other manufacturers in the market. This memo advises on switching to other sulfonylureas. If it is not considered appropriate to switch patients, unlicensed imports of glibenclamide tablets are available.

The MMT will be contacting relevant practices who are currently prescribing this product.

SHORTAGES

Delmosart 18mg prolonged-release tablets are out of stock until mid-November 2019. All other strengths remain available. Prescribers may consider switching to another brand (Concerta XL; Matoride XL; Xaggitin XL; ;Xenidate XL – all bioequivalent and clinically appropriate).

UK licensed Jext 300mcg devices are currently unavailable. The MHRA has imported an unlicensed Austrian import which is equivalent to Jext and is accompanied by an Austrian German language pack, label and patient information leaflet (PIL) but will also contain a UK PIL.

SSRI'S SPC UPDATE

Last month's newsletter informed prescribers regarding SPC updates for Efexor XL (venlafaxine) and Lustral (sertraline) to warn that SSRIs may cause symptoms of sexual dysfunction, with reports of long-lasting sexual dysfunction where the symptoms have continued despite treatment discontinuation.

Cipralext (citalopram) has now revised the SPC to reflect this also;

[Revised SPC: Cipralext \(escitalopram\) products](#)

SPC now advises that there have been reports of long-lasting sexual dysfunction where the symptoms have continued despite discontinuation of SSRIs.

SAFETY ALERTS DIRECT TO PRACTICES VIA CENTRAL ALERTING SYSTEM

On 1st October 2019 the MHRA started sending safety alerts directly to practices from its central alerting system (CAS), which replaces local email alerting arrangements. CAS will be one of the main channels used to communicate information during EU exit.

For full information and registration form click the link below :-

[MHRA urging GP practices to register for safety alerts on its portal](#)

For general enquiries please email: donccg.medicinesmanagementadmin@nhs.net

For practice pharmacist queries please email: donccg.rxline@nhs.net

SELF CARE

Self-care week

The 18th to the 22nd November 2019 is self-care week. The CCG will be running a social media campaign to promote self-care. Alongside this we have updated our support materials in response to practice request which are [available online](#) and will be brought to practices by the team:

- a self-care position statement for patients
- a position statement for prescribers
- a list of licensed indications for OTC products for prescriber/ receptionist use
- a leaflet for patients.
- an animation for reception areas.
- In the New Year a Care Navigation Template will be made available, incorporating self-care routes.

This information will be available through self-care week to promote to patients and practice can use this to re-focus their efforts on self-care prescribing reduction from the 25th November onwards.

August update:

In August 2019 Doncaster practices prescribed £7321 more of self-care items than they did in August last year. So far this year we have spent £16k more on products for conditions that should resolve without treatment than we did last year. Current spend stands at £261k.

Non ACBS Suncream items prescribed in August were:

Sunsense_Sunsensitive Crm SPF 50+ (130801000BBNVA0)	4
THE BURNS PRACTICE (C86007)	1
THE TICKHILL & COLLIERY MEDICAL PRACTICE (C86013)	2
THORNE MOOR MEDICAL PRACTICE (C86614)	1
Sunsense_Toddler Suncare Milk Spf 50+ (130801000BBMAA0)	3
CONISBROUGH GROUP PRACTICE (C86024)	3
Ultrasun_Anti-Aging Face Crm SPF 30 (130801000BBPHA0)	1
MEXBOROUGH HEALTH CENTRE (C86005)	1
Ultrasun_Family Lot SPF 30 (130801000BBPFA0)	1
MEXBOROUGH HEALTH CENTRE (C86005)	1

For general enquiries please email: donccg.medicinesmanagementadmin@nhs.net

For practice pharmacist queries please email: donccg.rxline@nhs.net

Below is a list of 112 items of general multivitamins prescribed in August that are likely to have been for minor conditions (i.e. not all the prescribing of these items). £133 was spend on Abidec, £169 on soluble Forceval and a whopping £20 per pack on Vega_ZM3 Multivit/Min V/Cap

Row Labels	Sum of Items	Row Labels	Sum of Items
Abidec_Dps (090607000BBFJBF)	35	Multivit_Tab (090607000AABBBB)	10
ASKERN MEDICAL PRACTICE (C86605)	2	FRANCES STREET MEDICAL CENTRE (C86025)	1
CONISBROUGH MEDICAL PRACTICE (C86625)	1	HATFIELD HEALTH CENTRE (C86003)	1
DUNSVILLE MEDICAL CENTRE (C86611)	2	KINGTHORNE GROUP PRACTICE (C86017)	1
EDLINGTON HEALTH CENTRE PRACTICE (C86026)	1	MOUNT GROUP PRACTICE (C86011)	2
FIELD ROAD SURGERY (C86037)	1	ST VINCENT MEDICAL CENTRE (C86029)	1
FRANCES STREET MEDICAL CENTRE (C86025)	1	THE LAKESIDE PRACTICE (C86016)	1
GREAT NORTH MEDICAL GROUP (C86001)	1	THE VILLAGE GROUP PRACTICE (C86609)	1
HATFIELD HEALTH CENTRE (C86003)	3	WHITE HOUSE FARM MEDICAL CENTRE (C86021)	2
KINGTHORNE GROUP PRACTICE (C86017)	5		
MEXBOROUGH HEALTH CENTRE (C86005)	1	Sanatogen Complete_A-Z Tab OAD (091000000BKSAO)	4
MOUNT GROUP PRACTICE (C86011)	3	EDLINGTON HEALTH CENTRE PRACTICE (C86026)	1
NORTHFIELD SURGERY (C86018)	1	ST VINCENT MEDICAL CENTRE (C86029)	2
REGENT SQUARE GROUP PRACTICE (C86006)	1	THE NEW SURGERY (C86034)	1
ST.JOHNS GROUP PRACTICE (C86020)	1		
THE FLYING SCOTSMAN HEALTH CENTRE (Y05167)	5	Sanatogen_Vital 50+ Tab OAD (091000000BBLWA0)	2
THE NAYAR PRACTICE (C86033)	1	DUNSVILLE MEDICAL CENTRE (C86611)	1
THE NEW SURGERY (C86034)	1	THE NEW SURGERY (C86034)	1
THE RANSOME PRACTICE (C86002)	1		
THE VILLAGE GROUP PRACTICE (C86609)	1	Valupak_Multivit & Iron Tab OAD (091000000BBPFA0)	1
WHITE HOUSE FARM MEDICAL CENTRE (C86021)	2	THE NEW SURGERY (C86034)	1
Baby D_Oral Soln 1,000/ml (0906040G0BHAABN)	2	Valupak_Multivit & Mineral Tab OAD (091000000BBPPA0)	9
MOUNT GROUP PRACTICE (C86011)	2	ASKERN MEDICAL PRACTICE (C86605)	1
Forceval Jnr_Tab Solb (090607000BBLDA0)	1	EDLINGTON HEALTH CENTRE PRACTICE (C86026)	2
BARNBURGH SURGERY (C86606)	1	PETERSGATE MEDICAL CENTRE (C86038)	1
Forceval_Tab Solb (090607000BBLCA0)	15	ST.JOHNS GROUP PRACTICE (C86020)	1
CONISBROUGH MEDICAL PRACTICE (C86625)	1	THE ROSSINGTON PRACTICE (C86015)	1
DUNSVILLE MEDICAL CENTRE (C86611)	2	THE SANDRINGHAM PRACTICE (C86022)	2
GREAT NORTH MEDICAL GROUP (C86001)	1	THE VILLAGE GROUP PRACTICE (C86609)	1
MOUNT GROUP PRACTICE (C86011)	2		
NORTHFIELD SURGERY (C86018)	2	Valupak_Multivit Tab OAD (090607000BBIKBB)	31
PETERSGATE MEDICAL CENTRE (C86038)	1	CONISBROUGH MEDICAL PRACTICE (C86625)	2
ST.JOHNS GROUP PRACTICE (C86020)	1	DUNSVILLE MEDICAL CENTRE (C86611)	5
THE BURNS PRACTICE (C86007)	1	FIELD ROAD SURGERY (C86037)	1
THE RANSOME PRACTICE (C86002)	1	GREAT NORTH MEDICAL GROUP (C86001)	2
THE SANDRINGHAM PRACTICE (C86022)	1	MEXBOROUGH HEALTH CENTRE (C86005)	1
THE SCOTT PRACTICE (C86019)	2	MOUNT GROUP PRACTICE (C86011)	1
THE VILLAGE GROUP PRACTICE (C86609)	1	PETERSGATE MEDICAL CENTRE (C86038)	2
THORNE MOOR MEDICAL PRACTICE (C86614)	1	REGENT SQUARE GROUP PRACTICE (C86006)	5
		THE NAYAR PRACTICE (C86033)	5
Vega_ZM3 Multivit/Min V/Cap (091000000BBNAA0)	2	THE OAKWOOD SURGERY (C86012)	1
GREAT NORTH MEDICAL GROUP (C86001)	2	THE ROSSINGTON PRACTICE (C86015)	2
		THE SANDRINGHAM PRACTICE (C86022)	3
		THE SCOTT PRACTICE (C86019)	1
		Grand Total	112

For general enquiries please email: donccg.medicinesmanagementadmin@nhs.net

For practice pharmacist queries please email: donccg.rxline@nhs.net

INFORMATION

UNLICENSED SPECIALS FLOWCHART

A flowchart has been developed to support Primary Care Prescribers when asked to prescribe Unlicensed Specials by Secondary Care Specialists in line with DBTHFT Trust Policy. The flowchart is on the MMT website and can be found in the Guidance section.

To view the flowchart [Click Here](#)

OPIOID REDUCTION – CONSULTANT CONNECT

The CCG continues to work with providers and PCNs to implement strategies to “turn off the tap” of new opioid prescribing and assist those who have unfortunately become more dependent on opioids than is desirable.

Prescribers are reminded that advice can be sought via consultant connect on designing plans to reduce opioid use in dependent patients from the pain speciality.

APC PRESCRIBING COMMITTEE OCTOBER UPDATE

Memantine has been reviewed from Amber to **Green G** in line with recent NICE guidance that supports GP’s initiating if confident to do so otherwise patients can be referred into the mental health team where appropriate.

Tadalafil dosed **once daily** was given a **Grey** TLS status. Due to the long half-life of tadalafil the higher dose twice weekly is just as effective. Tadalafil daily is in the national list of drugs that should not be routinely prescribed in primary care. 2.5mg and 5mg tadalafil will be separated from the 10mg and 20mg PRN dose strengths that are Green-G and will be given a Grey 5 status.

Cleen enemas were classified as **Amber G** for the indication of occasional constipation. The other indication of large volume bowel cleansing (Fleet) is to be left as Red

Antacid & Oxetacaine (all brands) used post radiotherapy has been classified as **Amber G**

Botulinum toxin type A (Xeomin) used for chronic sialorrhoea caused by neurological conditions in adults has been classified as **Red 1,2**

Larotrectinib (Vitrakvi) used for solid tumours that display a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion has been classified as **Grey 2**

Neratinib (Nerlynx) used for early-stage hormone receptor positive HER2-overexpressed/amplified breast cancer who have completed adjuvant trastuzumab-based therapy <1 year ago has been classified as **Red 1,2**

For general enquiries please email: donccg.medicinesmanagementadmin@nhs.net

For practice pharmacist queries please email: donccg.rxline@nhs.net

DONCASTER AND BASSETLAW FORMULARY LIAISON GROUP UPDATE

The Insulin and Antidiabetic drugs sections (Section [6.1.1](#) and [6.1.2](#)) of the formulary have been reviewed, updated and ratified with the input of endocrinologists and GPwSI in diabetes. The changes relevant to primary care are:

- FIASP® (insulin aspart) is now on the formulary, which replaces Novorapid.
- Semglee® and Toujeo® have been added onto the formulary as insulin glargine formulations. Semglee® is a biosimilar to Lantus® and Abasaglar®. Toujeo is a high strength insulin preparation and therefore not interchangeable with the others. Prescribers are reminded that insulin glargine is a biological medicine and therefore must be prescribed and dispensed by brand name.
- Semaglutide (Ozempic® solution for injection) has been added onto the formulary as the once-weekly glucagon-like peptide-1 (GLP-1) receptor agonist of choice. Liraglutide (Victoza®) remains the daily GLP-1 receptor agonist of choice.
- Ertugliflozin, a Sodium glucose cotransporter-2 (SGLT-2) inhibitor, was added onto the formulary. Ertugliflozin has the lowest acquisition cost amongst the SGLT-2 inhibitors but should be reserved for diabetic patients with low cardiovascular risk. Canagliflozin and Empagliflozin demonstrated significant cardiovascular events reduction in clinical trials and therefore remain first line choices.

CANNABIS-BASED PRODUCTS FOR MEDICINAL USE TRAINING PACKAGE

Please find below links to the training package regarding Cannabis-based Products for Medicinal Use developed by NHSE- I and HEE and the Government response to the Health and Social Care Committee on medicinal cannabis.

Any Healthcare professionals can register to do the training, please be aware that this may require an NHS.net email address.

<https://www.e-lfh.org.uk/programmes/cannabis-based-products-for-medicinal-use>

https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/829762/government-response-to-the-health-and-social-care-committee-report-on-drugs-policy-medicinal-cannabis.pdf

ANTIMICROBIAL GUIDANCE FOR DONCASTER AND BASSETLAW

The updated antimicrobial guidance for the Doncaster and Bassetlaw area has now been agreed and is accessible via the infections guidance or formulary sections of the MMT website. This document is hosted by Bassetlaw CCG. [Click here](#) to view.


The 18th-22nd of November 2019 is antibiotic awareness week (as well as self-care week). The CCG will be running a social media campaign to support this. Your locality lead pharmacists also have access to an antimicrobial report by practice and by PCN which they

For general enquiries please email: donccg.medicinesmanagementadmin@nhs.net



For practice pharmacist queries please email: donccg.rxline@nhs.net

will be able to use to discuss trends with you. Below are 2 examples for rising items/ STAR-PU:


Quinolones

Primary Care Network	Q1 18/19	Q2 18/19	Q3 18/19	Q4 18/19	Q1 19/20	Trend
4 Doncaster	3.73	3.48	3.25	3.03	3.22	

Cephalosporins

Primary Care Network	Q1 18/19	Q2 18/19	Q3 18/19	Q4 18/19	Q1 19/20	Trend
4 Doncaster	6.25	5.54	4.72	4.52	5.69	
East	5.94	6.52	6.42	5.43	6.01	

Overall across the area the message it positive, GP practices on average are reducing prescribers of antimicrobials and hopefully this trend can be maintained:



https://openprescribing.net/measure/ktt9_antibiotics/ccg/02X/

For general enquiries please email: donccg.medicinesmanagementadmin@nhs.net

For practice pharmacist queries please email: donccg.rxline@nhs.net